Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

ADDTed Dec. 4 at 9:35 PM

$IBRX If anyone else is looking for another early stage biotech, check out $TLSA (Tiziana). Going after early stage dementia/Alzheimers by reducing inflammation. Will be just like Immunity bio from a TAM perspective.

1 · Reply

HopehelpsU Dec. 4 at 9:10 PM

$TLSA AI....but the rational is beyond acceptable imho.... https://share.google/aimode/FfEHIqc6CNVWur9LS

0 · Reply

Marcus1927 Dec. 4 at 8:42 PM

$TLSA from LSE ... not my words.. but feeling the same; ''Another tanking share price today currently $1.64 down from $1.90 yesterday, says everything about the confidence in this share. Shareholders about to get shafted yet again with yet another scam AKA spinoff, GC gets annual rewards for these whilst shareholders sit with another non liquid "asset". 5 years later we are still waiting for Accustem to reward patient shareholders and GC has always remained invisible during this period.''

1 · Reply

HopehelpsU Dec. 4 at 7:12 PM

$TLSA So I'm assuming the gov shutdown set us back a bit... ODD news is imminent! 🤪...... Strap in!

0 · Reply

HopehelpsU Dec. 4 at 6:56 PM

$TLSA March 24th 2025 was the last time Tiziana had mentioned ODD...8 months ago 0001013762-25-001691.pdf https://share.google/fldl71kh9AQJ4dWvI

1 · Reply

HopehelpsU Dec. 4 at 5:12 PM

$TLSA There was a new submission of requested data for ODD.... The company claimed to have sent that info in months ago. This would put this as high as $4....settling somewhere between $3.X &$4.....

2 · Reply

HopehelpsU Dec. 4 at 5:10 PM

$TLSA It's time for the ODD news.... Do it! It's possible the company was saving it for a rainy 🌧 day....

0 · Reply

GoCubsGo1124 Dec. 4 at 2:41 PM

$TLSA https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-plans-to-spinout-il-6-asset-into-separate-nt9x56sb79hz.html

0 · Reply

GoCubsGo1124 Dec. 4 at 2:00 PM

$TLSA neutral to slightly bearish to extremely bullish? What are we doing? Going up? Going down? This thing I swear

1 · Reply

Varus_q Dec. 4 at 10:41 AM

$TLSA I get that the old AccuStem spin-out left a bad taste for long-term holders. But this new spin-out feels very different — and the timing honestly screams that Tiziana is preparing the structure for a potential Foralumab transaction. Here’s why: - Foralumab needs to be valued as a standalone asset, separating it makes the valuation cleaner. - Big Pharma rarely wants to acquire an entire mixed pipeline, they prefer a single, de-risked asset. - Buyers want the corporate structure clean before topline data, not after. - M&A conversations often intensify right before a data readout, this is when interest peaks and negotiations happen quietly. Put together, the timing doesn’t look random. It looks planned. Not financial advice — DYOR.

1 · Reply

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Nov 25, 2025, 8:30 AM EST - 10 days ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 22 days ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 31, 2025, 9:43 AM EDT - 4 weeks ago

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot

Oct 29, 2025, 7:00 AM EDT - 5 weeks ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 2 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 2 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 2 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 9, 2025, 10:04 AM EDT - 3 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Sep 5, 2025, 8:30 AM EDT - 3 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 4 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 4 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 6 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 6 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 7 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 8 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 9 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 9 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 9 months ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 10 months ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 10 months ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 10 months ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 10 months ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 10 months ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 11 months ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 11 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 11 months ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 11 months ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Jun 28, 2024, 11:01 AM EDT - 1 year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

May 30, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

May 13, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Apr 25, 2024, 10:00 AM EDT - 1 year ago

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Mar 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

ADDTed Dec. 4 at 9:35 PM

1 · Reply

HopehelpsU Dec. 4 at 9:10 PM

$TLSA AI....but the rational is beyond acceptable imho.... https://share.google/aimode/FfEHIqc6CNVWur9LS

0 · Reply

Marcus1927 Dec. 4 at 8:42 PM

1 · Reply

HopehelpsU Dec. 4 at 7:12 PM

$TLSA So I'm assuming the gov shutdown set us back a bit... ODD news is imminent! 🤪...... Strap in!

0 · Reply

HopehelpsU Dec. 4 at 6:56 PM

$TLSA March 24th 2025 was the last time Tiziana had mentioned ODD...8 months ago 0001013762-25-001691.pdf https://share.google/fldl71kh9AQJ4dWvI

1 · Reply

HopehelpsU Dec. 4 at 5:12 PM

$TLSA There was a new submission of requested data for ODD.... The company claimed to have sent that info in months ago. This would put this as high as $4....settling somewhere between $3.X &$4.....

2 · Reply

HopehelpsU Dec. 4 at 5:10 PM

$TLSA It's time for the ODD news.... Do it! It's possible the company was saving it for a rainy 🌧 day....

0 · Reply

GoCubsGo1124 Dec. 4 at 2:41 PM

$TLSA https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-plans-to-spinout-il-6-asset-into-separate-nt9x56sb79hz.html

0 · Reply

GoCubsGo1124 Dec. 4 at 2:00 PM

$TLSA neutral to slightly bearish to extremely bullish? What are we doing? Going up? Going down? This thing I swear

1 · Reply

Varus_q Dec. 4 at 10:41 AM

1 · Reply

GoCubsGo1124 Dec. 3 at 11:38 PM

$TLSA needs to pull a move like $PLRZ and it’s intranasal results. Except without the reverse split like they had?

1 · Reply

GoCubsGo1124 Dec. 3 at 8:52 PM

$TLSA while the number is not significant, we have gained more watchers in the last day or two then we have in the last two months. Bullish sentiment, news of phase 2 should be on the way. Let’s see

0 · Reply

DataJim Dec. 3 at 7:06 PM

$TLSA Accustem was a disaster because it launched during COVID chaos with poor communication, no clear listing plan, and a weak asset (StemPrintER). Shares ended up on illiquid pink sheets, causing long-lasting frustration. The new anti-IL-6 spinout is fundamentally different: it’s a real, clinically relevant asset, Tiziana plans a proper exchange listing, and management learned from the Accustem mistakes. This spinout has strategic purpose and much better execution, so Accustem doesn’t reduce confidence in it.

2 · Reply

Ic0gcds000 Dec. 3 at 5:44 PM

$TLSA where is CEO cerrone He should be informing shareholders of his actions rather than show contempt Speaks volumes of his regard!!!

1 · Reply

GoCubsGo1124 Dec. 3 at 5:26 PM

$TLSA @Marcus1927 with all due respect, been here a good long while. It’s not a good look when you randomly show up on a board with a profile that was created on December 3, 2025, and you start blowing up the chat. It just doesn’t look reputable..

3 · Reply

Marcus1927 Dec. 3 at 4:43 PM

$TLSA screwing shareholders again and again

1 · Reply

Marcus1927 Dec. 3 at 4:42 PM

$TLSA sell before spin off! will go to pennys

1 · Reply

ppl_first Dec. 3 at 4:40 PM

$TLSA 1.64 by 2pm, calling it now, then turnaround to 1.75

0 · Reply

ppl_first Dec. 3 at 4:39 PM

$TLSA Waiting for 1.63-1.65 buypoint. Happened today and I missed it. This shell of a company remaining after the spin-off aint gonna be worth shit until the rest of the pipeline catches up. Buy 1.63 sell 1.75

1 · Reply

rp6577 Dec. 3 at 4:21 PM

$TLSA is a little bit annoying that they announce the spin out before the phase 2 results. However, we should still see a strong rally once they are released in the next few weeks

0 · Reply

Marcus1927 Dec. 3 at 4:15 PM

$TLSA they always spin off and shaft shareholders!

0 · Reply

Marcus1927 Dec. 3 at 4:02 PM

$TLSA reminds me of accustem spin off- do they ever learn?

1 · Reply

Market Cap	209.16M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	209,100
Avg Vol	311,728
Day's Range	N/A - N/A
Shares Out	116.85M
Stochastic %K	65%
Beta	-0.05
Analysts	Strong Buy
Price Target	$3.00